Inosine

Inosine

SCHEMBL21840403

Nc1ncnc2[nH]cnc12.OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.72
DOT1L Q8TEK3 2/20 0.72
DPP4 P27487 1/20 0.72
MEN1 O00255 1/20 0.72
SLC28A1 O00337 1/20 0.72
MAP3K7 O43318 1/20 0.72
SLC28A2 O43868 1/20 0.72
GAPDH P04406 1/20 0.72
MAPK1 P28482 1/20 0.72
ADORA2A P29274 1/20 0.72
ADORA2B P29275 1/20 0.72
ADORA1 P30542 1/20 0.72
STAT6 P42226 1/20 0.72
PI4KA P42356 1/20 0.72
KMT2A Q03164 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
PI4K2B Q8TCG2 1/20 0.72
SLC29A1 Q99808 1/20 0.72
PI4K2A Q9BTU6 1/20 0.72
SLC28A3 Q9HAS3 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vidarabine SCHEMBL27371675 0.94 ADORA3 (0.81) ADORA3DOT1LDPP4MEN1SLC28A1
Adenosine SCHEMBL536558 0.94 ADORA3 (0.81) ADORA3DOT1LDPP4MEN1SLC28A1
Adenosine SCHEMBL1664893 0.90 ADORA3 (0.89) ADORA3DOT1LDPP4MEN1SLC28A1
Inosine SCHEMBL21840404 0.87 ADORA3 (0.66) ADORA3DOT1LDPP4MEN1SLC28A1
Adenosine SCHEMBL23201584 0.86 ADORA3 (0.68) ADORA3DOT1LDPP4MEN1SLC28A1
Vidarabine SCHEMBL27261659 0.86 ADORA3 (0.71) ADORA3DOT1LDPP4MEN1SLC28A1
Inosine SCHEMBL298755 0.85 SLC29A1 (0.75) ADORA3DOT1LDPP4MEN1SLC28A1
Inosine SCHEMBL2046912 0.85 SLC29A1 (0.75) ADORA3DOT1LDPP4MEN1SLC28A1
Inosine SCHEMBL6748954 0.85 SLC29A1 (0.75) ADORA3DOT1LDPP4MEN1SLC28A1
Inosine SCHEMBL18653532 0.85 SLC29A1 (0.75) ADORA3DOT1LDPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115372-A1 COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES ARRAKIS THERAPEUTICS, INC. 2020-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115372-A1 COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES NSUN3, NSUN2, POLRMT ADORA3 1860/4885DOT1L 309/4885DPP4 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.